Publications by authors named "A DUJARDIN"

Introduction: Immunoglobulin A nephropathy (IgAN) associated with cirrhosis is frequent but often overlooked because it is largely considered silent. Until now, little has been known about their presentation and outcomes.

Methods: We conducted a retrospective multicenter study on patients with kidney biopsy-proven cirrhosis-related IgAN (cirrhosis-IgAN), diagnosed between 2009 and 2022.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines kidney transplantation outcomes for patients with renal AA amyloidosis, revealing previously unclear results regarding survival and disease recurrence, mostly based on older data.
  • Conducted as a retrospective multicenter cohort study, it analyzed patients who underwent transplantation in France from 2008 to 2018, focusing on factors like age and treatment methods.
  • Results indicated high survival rates (94% at 1 year, 85.5% at 5 years) but also significant complications, including infection (55.8%) and acute rejection episodes (27.9%), with a low recurrence rate of amyloidosis (5.8%).
View Article and Find Full Text PDF

We used all-atom Molecular Dynamics (MD) computer simulations to study the formation of pre-polymers between the four nucleotides in RNA (AMP, UMP, CMP, GMP) in the presence of different substrates that could have been present in a prebiotic environment. Pre-polymers are C3'-C5' hydrogen-bonded nucleotides that have been suggested to be the precursors of phosphodiester-bonded RNA polymers. We simulated wet-dry cycles by successively removing water molecules from the simulations, from ~60 to 3 water molecules per nucleotide.

View Article and Find Full Text PDF

Histone H3 trimethylation on lysine 9 (H3K9me3) is a defining feature of mammalian pericentromeres, loss of which results in genome instability. Here we show that CDYL2 is recruited to pericentromeres in an H3K9me3-dependent manner and is required for faithful mitosis and genome stability. CDYL2 RNAi in MCF-7 breast cancer cells and Hela cervical cancer cells inhibited their growth, induced apoptosis, and provoked both nuclear and mitotic aberrations.

View Article and Find Full Text PDF
Article Synopsis
  • Ruxolitinib is an effective treatment for steroid-refractory graft-versus-host disease (SR-GVHD), with overall response rates exceeding 70%, but it increases the risk of cytomegalovirus (CMV) reactivation.
  • A study of 57 patients showed that starting ruxolitinib significantly raised the chances of first CMV (HR=1.747) and Epstein-Barr virus (EBV) reactivation (HR=2.657).
  • Despite the risk of viral reactivation, ruxolitinib's benefits in treating SR-GVHD are substantial, highlighting the need for careful monitoring of viral loads rather than restricting its use.
View Article and Find Full Text PDF